FDA recalls 2 million baked goods over listeria risk
Listen to article
The US Food and Drug Administration (FDA) has issued a recall for around 2 million baked goods, including various types of doughnuts, due to the risk of Listeria monocytogenes contamination.
The recall affects 60 products manufactured by FGF Brands, a wholesale pastry supplier that distributes baked goods in the United States and Canada.
According to the FDA, the affected products—produced before 13 December 2024—include flavoured and filled doughnuts, cinnamon sticks, French crullers, and fritters. Some of these were also sold at Dunkin'.
Recall Classification and Consumer Advisory
Initially announced on 7 January, the recall was upgraded to a Class II recall on Wednesday. Under FDA guidelines, this classification is applied when consuming the product could lead to temporary or medically reversible health effects, while the risk of severe consequences remains low.
The FDA has not provided further instructions for consumers at this stage. FGF Brands has yet to comment on the recall. Customers can reach the company by phone at +1 905-761-3333 or via email at info@fgfbrands.com. A full list of affected products is available on the FDA's website.
Risks of Listeria Contamination
The bacterium Listeria monocytogenes can cause listeriosis, a serious foodborne infection. According to the Centers for Disease Control and Prevention (CDC), listeria is among the leading causes of death from foodborne illness in the US, with approximately 1,600 cases and 260 deaths reported annually.
Symptoms of listeriosis include:
Fever
Muscle aches
Headache
Stiff neck
Confusion
Loss of balance
Convulsions
Diarrhoea and other gastrointestinal symptoms
For pregnant women, infection can result in miscarriage, stillbirth, premature birth, or severe illness in newborns.
Health authorities advise individuals in high-risk categories to seek medical attention if they develop flu-like symptoms within two months of consuming contaminated food.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
04-06-2025
- Business Recorder
French singer Nicole Croisille, of ‘A Man and a Woman' fame, dies at 88: agent
PARIS: Nicole Croisille, a French singer who sang on the soundtrack of the hit 1966 film 'A Man and a Woman', has died, her agent told AFP on Wednesday. She was 88. Croisille died 'following a long illness' in Paris during the night of Tuesday-Wednesday, Jacques Metges said. 'Until the end, she fought with lots of force and courage,' he added. Croisille was best known internationally for her work on the film soundtrack of 'A Man and a Woman', including the solo 'Today it's You' and several duets. Rome's 'Hollywood on the Tiber' plans comeback despite Trump tariff threat She was also beloved in France for other hits during the 1970s including 'Telephone-moi' (Call me), 'Parlez-moi de lui' (Tell me about him) and 'Une femme avec toi' (A woman with you). 'I have only sung love songs and I know what I have brought to people,' she said in an interview with Paris Match in 2017. In addition to singing, Croisille was also a dancer and an actress.
Express Tribune
02-06-2025
- Express Tribune
Sanofi's $9.5B acquisition of Blueprint Medicines strengthens rare immunology portfolio
In a major move underscoring its ambition to lead in rare diseases and immunology, French pharmaceutical giant Sanofi announced its plan to acquire US-based Blueprint Medicines for up to $9.5 billion. The deal was announced by a press release on Sanofi's website. It is the largest by a European healthcare company this year and will see Sanofi paying $129 per share in cash, a significant premium that sent Blueprint's stock soaring in premarket trading. Blueprint Medicines, known for its specialty in treating systemic mastocytosis a rare blood disorder marked by the overproduction of mast cells brings to Sanofi a strong foothold in a niche yet critical area of medicine. The acquisition adds the FDA-approved drug Ayvakit, the only treatment for advanced systemic mastocytosis, to Sanofi's growing immunology portfolio. Sanofi CEO Paul Hudson framed the deal as a strategic leap forward, enhancing the company's pipeline and reinforcing its transformation into a global leader in immunology. We announced an agreement to acquire Blueprint Medicines, a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases. — Sanofi (@sanofi) June 2, 2025 With a promising pipeline including next-generation therapies like elenestinib and BLU-808, the acquisition fits into Sanofi's broader ambition of innovation despite recent setbacks, including a failed lung disease drug trial. Industry analysts from JP Morgan praised the acquisition for its strategic and financial merits, forecasting Ayvakit could generate $2 billion in annual sales by 2030. Sanofi's ongoing spree of acquisitions, including Vigil Neuroscience and Inhibrx, signals a company doubling down on R&D investments to reshape its future. The acquisition aligns with Sanofi's broader strategy to invest heavily in US manufacturing and research, tapping into incentives and momentum driven by recent government policies. With Blueprint Medicines now joining its portfolio, Sanofi cements its stake in cutting-edge immunology treatments and rare disease therapies, positioning itself for long-term growth in a competitive pharmaceutical landscape.
Business Recorder
31-05-2025
- Business Recorder
US FDA approves Moderna's next-generation COVID vaccine for adults 65 or older
The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, the company said on Saturday, the first endorsement since the regulator tightened requirements. The vaccine has also been approved for people aged 12 to 64 with at least one or more underlying risk factors defined by the Centers for Disease Control and Prevention, Moderna said in a statement. The company said it expects to have the vaccine, called mNEXSPIKE, available for the 2025-2026 respiratory virus season. 'The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,' CEO Stephane Bancel said in the statement. The Department of Health and Human Services, under the leadership of long-time vaccine skeptic Robert F. Kennedy Jr., is tightening regulatory scrutiny on vaccines. The FDA said on May 20 it planned to require drugmakers to test their COVID booster shots against an inert placebo in healthy adults under 65 for approval, effectively limiting them to older adults and those at risk of developing severe illness. The Moderna vaccine can be stored in refrigerators rather than freezers, to offer longer shelf life and make distribution easier, especially in developing countries where supply-chain issues could hamper vaccination drives. The Centers for Disease Control and Prevention, which Kennedy also oversees, said on Thursday that COVID vaccines remain an option for healthy children when parents and doctors agree that it is needed, stopping short of Kennedy's announcement days earlier that the agency would remove the shots from its immunization schedule. The CDC announcement eases investor concern to some extent, analysts say, as it keeps the existing framework for older adults and at-risk people who generally seek out the shots. FDA leaders have said 100 million to 200 million Americans would still be eligible for annual shots. Moderna is betting on its newer messenger RNA vaccines as it grapples with waning demand for its original COVID vaccine Spikevax and lower-than-expected uptake of its respiratory syncytial virus vaccine. The approval for mNEXSPIKE was based on late-stage trial data, which showed the shot was not inferior in efficacy compared to Spikevax in individuals aged 12 years and older. The shot also showed superior efficacy compared to Spikevax in adults 18 years of age and older in the study. Kennedy has kickstarted a major overhaul of health departments, laying off thousands of employees to align with President Donald Trump's goal of dramatically shrinking the federal government. This has further ignited worries about potential disruptions to the regulatory review of treatments and vaccines. The CDC's outside panel of vaccine experts in April discussed recommending the booster shots only for populations at risk of severe COVID-19 for the upcoming immunization campaign. The FDA approved Novavax's COVID vaccine Nuvaxovid this month, limiting its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness. Conditions that constitute additional risk range from illnesses such as diabetes and heart disease to behaviors like physical inactivity and substance abuse, according to the CDC. While Moderna's shots, as well as Pfizer-BioNTech's Comirnaty, are mRNA-based, Novavax's vaccine is protein-based and takes longer to manufacture. Moderna this month withdrew an application seeking approval for its flu-and-COVID combination vaccine candidate to wait for efficacy data from a late-stage trial of its influenza shot.
